AM Investment Strategies LLC cut its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,766 shares of the company’s stock after selling 274 shares during the quarter. Johnson & Johnson comprises 1.2% of AM Investment Strategies LLC’s investment portfolio, making the stock its 21st biggest position. AM Investment Strategies LLC’s holdings in Johnson & Johnson were worth $3,315,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Nordwand Advisors LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $785,273,000. Edmp Inc. raised its position in shares of Johnson & Johnson by 17,222.9% during the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock valued at $18,247,000 after buying an additional 3,204,658 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after buying an additional 2,815,655 shares in the last quarter. GQG Partners LLC grew its holdings in shares of Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after purchasing an additional 2,547,378 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after purchasing an additional 1,805,632 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Insiders Place Their Bets
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Johnson & Johnson Price Performance
NYSE:JNJ opened at $163.60 on Tuesday. The business’s 50-day simple moving average is $157.86 and its two-hundred day simple moving average is $167.04. The stock has a market cap of $426.06 billion, a PE ratio of 34.23, a P/E/G ratio of 2.78 and a beta of 0.53. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $2.67 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.66 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.91%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 94.56%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Insiders Drive Volatility For Keurig Dr Pepper
- After a 40% Drop, Analysts Remain Bullish on Impinj
- Visa Charges Higher After Better-Than-Expected Q2 Report
- onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
- Can Teladoc Stock Be Resuscitated?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
